Compare RNW & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RNW | VCEL |
|---|---|---|
| Founded | 2011 | 1989 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.4B |
| IPO Year | 2021 | 1996 |
| Metric | RNW | VCEL |
|---|---|---|
| Price | $6.84 | $39.84 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $7.00 | ★ $57.75 |
| AVG Volume (30 Days) | ★ 2.3M | 455.8K |
| Earning Date | 06-15-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 60.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $276,259,000.00 |
| Revenue This Year | N/A | $19.40 |
| Revenue Next Year | $11.50 | $18.24 |
| P/E Ratio | $14.63 | ★ N/A |
| Revenue Growth | N/A | ★ 16.45 |
| 52 Week Low | $4.39 | $28.95 |
| 52 Week High | $8.24 | $49.32 |
| Indicator | RNW | VCEL |
|---|---|---|
| Relative Strength Index (RSI) | 62.54 | 42.13 |
| Support Level | $6.78 | $35.32 |
| Resistance Level | $6.85 | $41.25 |
| Average True Range (ATR) | 0.03 | 1.23 |
| MACD | -0.02 | 0.15 |
| Stochastic Oscillator | 55.00 | 60.63 |
ReNew Energy Global PLC is a developer and operator of clean energy projects. Additionally, it provides clean energy solutions and value-added energy offerings through digitalization, storage, and carbon market services that are increasingly integral to addressing climate change. The company has two reportable segments: Generation and sale of renewable power and Manufacturing of power equipment. The majority of its revenue is generated from the Generation and sale of renewable power segment, which reflects the revenue earned from its utility-scale wind energy projects, solar energy projects, and hydro energy projects. The Manufacturing of power equipment segment relates to the manufacturing of solar panels and modules. Geographically, all of its material revenues are generated from India.
Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.